Literature DB >> 32896196

Gender discrepancies in bladder cancer: potential explanations.

Pravin Viswambaram1, Dickon Hayne2.   

Abstract

INTRODUCTION: Gender differences in urothelial carcinoma of the bladder (UCB) exist. Although men have a higher incidence of UCB, women tend to have poorer outcomes. We have explored and summarized the evidence for gender differences of UCB diagnosis and prognosis, together with reasons for these disparities. AREAS COVERED: The incidence of UCB is 3-4 times higher in men than women. However, women are more likely to be diagnosed with advanced disease. Women have a higher stage-for-stage mortality compared to men, and their greatest risk of death appears to be within the first 2 years of diagnosis. Survival outcomes following radical cystectomy (RC) and radiotherapy are also poorer in women. Delays in diagnosis, differences in female anatomy, as well as poorer surgical outcomes post-RC appear to contribute significantly to the disparities noted between genders. Other factors such as exposure to risk factors, differential hormone signaling, and carcinogen breakdown may also have a role. EXPERT OPINION: The gender divide in UCB outcomes has to be addressed. Improved medical and patient education and centralization of RC are recommended.

Entities:  

Keywords:  Bladder cancer; cystectomy; diagnosis; gender; outcomes; prognosis; women

Mesh:

Year:  2020        PMID: 32896196     DOI: 10.1080/14737140.2020.1813029

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  2 in total

1.  A Machine Learning-Based Investigation of Gender-Specific Prognosis of Lung Cancers.

Authors:  Yueying Wang; Shuai Liu; Zhao Wang; Yusi Fan; Jingxuan Huang; Lan Huang; Zhijun Li; Xinwei Li; Mengdi Jin; Qiong Yu; Fengfeng Zhou
Journal:  Medicina (Kaunas)       Date:  2021-01-22       Impact factor: 2.430

2.  Prognostic significance of SNCA and its methylation in bladder cancer.

Authors:  Zhengcun Wu; Chengxing Xia; Chao Zhang; Delin Yang; Kaili Ma
Journal:  BMC Cancer       Date:  2022-03-26       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.